Interviews

At the 12th annual meeting of the Pharmacy Quality Alliance held recently in Baltimore, Maryland, several speakers shared ideas on converting patient input into meaningful performance measures.

Jonathan Van Lare, PharmD, director of Pharmacy Advantage, discusses the growth of biosimilars in specialty pharmacy.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses how specialty pharmacies can differentiate themselves from the competition.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses how specialty pharmacists can help patients manage adverse events from their treatment regimen.

Gregory R. Morris, chief commercial officer at VirMedica, discusses the eAccess program for specialty pharmacies.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies help advance the goals of accountable care organizations.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses the largest challenges currently facing independent specialty pharmacies.

Mary M. Bridgeman, PharmD, BCPS, CGP, FASCP, clinical associate profession at the Ernesto Mario School of Pharmacy, Rutgers University, explains how pharmacy schools can optimize OTC training for students.

Mary M. Bridgeman, PharmD, BCPS, CGP, FASCP, clinical associate professor at the Ernesto Mario School of Pharmacy, Rutgers University, discusses whether pharmacy schools provide adequate OTC training.

Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.

Eric Peacock, CEO of MyHealthTeams, discusses effective treatment of patients with chronic conditions.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.

Rinku A. Patel, PharmD, RPh, discusses how to improve communication among patients, physicians, pharmacists, and payers.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses how specialty pharmacies can best position themselves to access limited distribution drugs.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses how specialty pharmacies can help patients gain access to costly specialty drug regimens.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses how communication can be improved among specialty pharmacies, manufacturers, and pharmacy benefit managers.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.

Rebekah L. Hanson, PharmD, BCPS, BCACP, discusses the elements of an effective patient management program in specialty pharmacy.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how pharmacies can help patients manage high drug costs.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.

Mark A. Vineis, vice president of Specialty Pharmacy at Cardinal Health, discusses how specialty pharmacies can help achieve the goals of accountable care organizations.

Deborah Michaelson, MS, RPh, vice president of Operations at Ardon Health, discusses how pharmacies can help patients overcome the cost of high co-pays to maintain specialty drug adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the impact of prior authorizations on specialty pharmacy.

Grant E. Knowles, PharmD, discusses how the projected growth in specialty drug spending may change the patient experience in the years ahead.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

Pharmacists need to remain aware of certain interactions that can occur with medications and nutraceuticals.